Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. We are also developing proprietary Lm-based antigen delivery products for patients suffering from more common cancers. Our lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors; ADXS-504, a Lm-based therapy for early-stage prostate cancer, and the intravenous gamma secretase inhibitor, AL101, for adenoid cystic carcinoma. AL102 (RINGSIDE) has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 segment of a pivotal study for patients with desmoid tumors.